FETUB

Summary

FETUB (fetuin B, HGNC:3658) is a protein-coding gene on chromosome 3q27.3, encoding Fetuin-B (Q9UGM5). Protease inhibitor required for egg fertilization.

The protein encoded by this gene is a member of the fetuin family, part of the cystatin superfamily of cysteine protease inhibitors. Fetuins have been implicated in several diverse functions, including osteogenesis and bone resorption, regulation of the insulin and hepatocyte growth factor receptors, and response to systemic inflammation. This protein may be secreted by cells.

Source: NCBI Gene 26998 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 74 total
• MANE Select transcript: NM_014375

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3658
Approved symbol	FETUB
Name	fetuin B
Location	3q27.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000090512
Ensembl biotype	protein_coding
OMIM	605954
Entrez	26998

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 14 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000265029, ENST00000382134, ENST00000382136, ENST00000420570, ENST00000431018, ENST00000435961, ENST00000450521, ENST00000488561, ENST00000898652, ENST00000898653, ENST00000898654, ENST00000898655, ENST00000898656, ENST00000898657, ENST00000898658, ENST00000898659, ENST00000898660

RefSeq mRNA: 9 — MANE Select: NM_014375 NM_001308077, NM_001308079, NM_001375587, NM_001375588, NM_001375589, NM_001375590, NM_001375591, NM_001375592, NM_014375

CCDS: CCDS3279, CCDS77871, CCDS82884

Canonical transcript exons

ENST00000265029 — 7 exons

Exon	Start	End
ENSE00001140642	186640399	186640685
ENSE00001177785	186652263	186653141
ENSE00003554385	186651218	186651301
ENSE00003586111	186641030	186641140
ENSE00003622550	186644751	186644920
ENSE00003623640	186642471	186642558
ENSE00003676295	186646248	186646349

Expression profiles

Bgee: expression breadth ubiquitous, 102 present calls, max score 95.17.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.6773 / max 285.5796, expressed in 41 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
40283	0.4961	24
40280	0.0781	16
40284	0.0698	14
40281	0.0179	5
40285	0.0119	5
40282	0.0035	2

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	95.17	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	94.12	gold quality
liver	UBERON:0002107	91.82	gold quality
lower esophagus mucosa	UBERON:0035834	79.06	gold quality
skin of abdomen	UBERON:0001416	69.06	gold quality
skin of leg	UBERON:0001511	68.94	gold quality
frontal pole	UBERON:0002795	67.04	gold quality
paraflocculus	UBERON:0005351	66.75	gold quality
middle frontal gyrus	UBERON:0002702	66.74	gold quality
oral cavity	UBERON:0000167	66.44	gold quality
esophagus mucosa	UBERON:0002469	66.39	gold quality
zone of skin	UBERON:0000014	65.28	gold quality
Brodmann (1909) area 10	UBERON:0013541	62.53	gold quality
endometrium epithelium	UBERON:0004811	61.37	gold quality
pharyngeal mucosa	UBERON:0000355	56.81	gold quality
cerebellar vermis	UBERON:0004720	56.27	gold quality
esophagus squamous epithelium	UBERON:0006920	56.27	silver quality
penis	UBERON:0000989	55.89	gold quality
vagina	UBERON:0000996	54.02	gold quality
rectum	UBERON:0001052	52.82	gold quality
thymus	UBERON:0002370	52.55	gold quality
quadriceps femoris	UBERON:0001377	51.57	gold quality
vastus lateralis	UBERON:0001379	51.04	gold quality
metanephros	UBERON:0000081	50.32	gold quality
hair follicle	UBERON:0002073	50.23	gold quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
layer of synovial tissue	UBERON:0007616	48.99	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.78

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1H4

miRNA regulators (miRDB)

13 targeting FETUB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-4663	99.62	65.33	957
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-8077	99.17	66.67	862
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-4266	98.53	67.29	1035
HSA-MIR-93-3P	98.15	66.65	1309
HSA-MIR-4660	97.79	67.44	1328
HSA-MIR-4786-5P	97.45	67.89	924
HSA-MIR-873-3P	96.84	66.09	786
HSA-MIR-1281	92.96	65.73	260

Literature-anchored findings (GeneRIF, showing 23)

• serum fetuin has a role in processing and transport of matrix gamma-carboxyglutamic acid protein and bone morphogenetic protein-2 in cultured human vascular smooth muscle cells (PMID:15280384)
• results support the hypothesis that fetuin-A serum levels are associated with bone cell activity (PMID:16797392)
• Reduced expression of fetuin-b led to a significant increase in the expression of lipogenic genes, thereby resulting in higher lipid levels. (PMID:22739111)
• Data indicate that fetuin-B was one of the highly expressed serum proteins in acute myocardial infarction. (PMID:25671698)
• serum level of fetuin B in the control subjects was lower than it in nonalcoholic fatty liver disease patients. fetuin B correlated with diastolic blood pressure, serum alanine transaminase and triglycerides, among the controls. It suggested a potential association between serum fetuin B and the presence of NAFLD. (PMID:27628583)
• Further studies need to elucidate factors contributing to fetuin B regulation in humans, as well as the pathophysiological significance of fetuin B upregulation in gestational diabetes (PMID:28183456)
• fetuin B may serve as a potential biomarker for coronary artery disease (PMID:28822077)
• Fetuin-A can alter insulin signaling and that fetuin-B may regulate glucose homeostasis via so far unknown effects, possibly on glucose effectiveness. (PMID:29138227)
• Fetuin B serum concentrations are not significantly different between patients with lipodystrophy (LD) and non-LD controls. (PMID:29153939)
• High Serum fetuin-B expression is associated with insulin resistance. (PMID:29194974)
• Increased serum fetuin-B level was significantly associated with higher risk of insulin resistance. Common genetic variants of FETUB SNPs (rs4686434, rs6785067, and rs3733159) were significantly associated with serum fetuin-B concentrations but were not associated with insulin resistance. (PMID:29390354)
• Patients with type 2 diabetes have significantly higher concentrations of plasma fetuin-B compared with normal glucose tolerance subjects and plasma fetuin-B is strongly associated with glucose and lipid metabolism, chronic inflammation and first-phase glucose-stimulated insulin secretion and insulin resistance. (PMID:29514765)
• Fetuin-B links nonalcoholic fatty liver disease (NAFLD) to type 2 diabetes (T2D) via inducing insulin resistance, and NAFLD contributes to the pathogenesis of T2D via multiple mechanisms. (PMID:29609136)
• Carrying the minor G allele for FETUB rs4686434 was significantly associated with decreased intrahepatic triglyceride content and may affect hepatic triglyceride accumulation in individuals at high risk of non-alcoholic fatty liver disease. (PMID:29671945)
• High Fetuin B expression is associated with vitamin D deficiency and pediatric obesity. (PMID:29684480)
• Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. (PMID:30601337)
• Serum fetuin-B level is correlated with fertilization rate in conventional IVF and it may be used as a predictive marker of fertilization in IVF treatment. (PMID:31073723)
• Association of Fetuin-B with Subclinical Atherosclerosis in Obese Chinese Adults. (PMID:31527322)
• The C-terminal region of human plasma fetuin-B is dispensable for the raised-elephant-trunk mechanism of inhibition of astacin metallopeptidases. (PMID:31604990)
• Fetuin-B regulates vascular plaque rupture via TGF-beta receptor-mediated Smad pathway in vascular smooth muscle cells. (PMID:32382986)
• Fetuin B overexpression suppresses proliferation, migration, and invasion in prostate cancer by inhibiting the PI3K/AKT signaling pathway. (PMID:32892030)
• Hepatokine Fetuin B expression is regulated by leptin-STAT3 signalling and associated with leptin in obesity. (PMID:35896788)
• Fetuin-B Overexpression Promotes Inflammation in Diabetic Retinopathy Through Activating Microglia and the NF-kappaB Signaling Pathway. (PMID:37883127)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	fetub	ENSDARG00000053973
danio_rerio	si:ch211-284e20.8	ENSDARG00000070918
mus_musculus	Fetub	ENSMUSG00000022871
rattus_norvegicus	Fetub	ENSRNOG00000001806

Paralogs (3): KNG1 (ENSG00000113889), HRG (ENSG00000113905), AHSG (ENSG00000145192)

Protein

Protein identifiers

Fetuin-B — Q9UGM5 (reviewed: Q9UGM5)

Alternative names: 16G2, Fetuin-like protein IRL685, Gugu

All UniProt accessions (5): Q9UGM5, C9JC68, E9PG08, F8WAW1, F8WEP7

UniProt curated annotations — full annotation on UniProt →

Function. Protease inhibitor required for egg fertilization. Required to prevent premature zona pellucida hardening before fertilization, probably by inhibiting the protease activity of ASTL, a protease that mediates the cleavage of ZP2 and triggers zona pellucida hardening.

Subcellular location. Secreted.

Tissue specificity. Liver and testis.

Similarity. Belongs to the fetuin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UGM5-1	1	yes
Q9UGM5-2	2, Beta

RefSeq proteins (9): NP_001295006, NP_001295008, NP_001362516, NP_001362517, NP_001362518, NP_001362519, NP_001362520, NP_001362521, NP_055190* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000010	Cystatin_dom	Domain
IPR001363	Prot_inh_fetuin_CS	Conserved_site
IPR025764	Cystatin_Fetuin_B	Domain
IPR046350	Cystatin_sf	Homologous_superfamily
IPR050735	Kininogen_Fetuin_HRG	Family

Pfam: PF00031

UniProt features (54 total): strand 16, helix 8, glycosylation site 5, disulfide bond 5, sequence conflict 5, sequence variant 3, compositionally biased region 3, domain 2, region of interest 2, signal peptide 1, chain 1, splice variant 1, turn 1, modified residue 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
7UAI	ELECTRON MICROSCOPY	2.8
6SAZ	X-RAY DIFFRACTION	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UGM5-F1	81.92	0.59

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 315

Disulfide bonds (5): 93–104, 117–137, 151–154, 216–224, 237–254

Glycosylation sites (5): 37, 136, 182, 289, 292

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 102 (showing top): GOBP_SINGLE_FERTILIZATION, GOBP_NEGATIVE_REGULATION_OF_PROTEOLYSIS, GOBP_NEGATIVE_REGULATION_OF_HYDROLASE_ACTIVITY, GNF2_HPN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_REGULATION_OF_HYDROLASE_ACTIVITY, GNF2_LCAT, GOBP_SPERM_EGG_RECOGNITION, CAIRO_HEPATOBLASTOMA_DN, MODULE_99, GOBP_REGULATION_OF_PEPTIDASE_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS

GO Biological Process (4): single fertilization (GO:0007338), binding of sperm to zona pellucida (GO:0007339), negative regulation of endopeptidase activity (GO:0010951), regulation of macromolecule metabolic process (GO:0060255)

GO Molecular Function (5): cysteine-type endopeptidase inhibitor activity (GO:0004869), metalloendopeptidase inhibitor activity (GO:0008191), enzyme inhibitor activity (GO:0004857), protein binding (GO:0005515), peptidase inhibitor activity (GO:0030414)

GO Cellular Component (3): extracellular region (GO:0005576), extracellular exosome (GO:0070062), obsolete extracellular space (GO:0005615)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
endopeptidase inhibitor activity	2
fertilization	1
sperm-egg recognition	1
endopeptidase activity	1
negative regulation of peptidase activity	1
regulation of endopeptidase activity	1
regulation of metabolic process	1
macromolecule metabolic process	1
cysteine-type endopeptidase activity	1
metalloendopeptidase activity	1
catalytic activity	1
enzyme regulator activity	1
molecular function inhibitor activity	1
binding	1
enzyme inhibitor activity	1
peptidase activity	1
peptidase regulator activity	1
cellular anatomical structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

938 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FETUB	ASTL	Q6HA08	701
FETUB	ORM2	P19652	597
FETUB	ORM1	P02763	581
FETUB	AHSG	P02765	570
FETUB	AGA	P20933	560
FETUB	EEA1	Q15075	549
FETUB	MSR1	P21757	547
FETUB	CETP	P11597	516
FETUB	COL1A2	P02464	503
FETUB	ALB	P02768	498
FETUB	SERPINA7	P05543	496
FETUB	KLK3	P07288	492
FETUB	GGCT	O75223	431
FETUB	RAB5A	P20339	425
FETUB	FAM151A	Q8WW52	421

IntAct

19 interactions, top by confidence:

A	B	Type	Score
FETUB	HSD17B13	psi-mi:“MI:0915”(physical association)	0.560
FETUB	DARS2	psi-mi:“MI:0915”(physical association)	0.560
CREB3L1	FETUB	psi-mi:“MI:0915”(physical association)	0.560
HSD17B13	FETUB	psi-mi:“MI:0915”(physical association)	0.560
MTIF3	FETUB	psi-mi:“MI:0915”(physical association)	0.560
FETUB	ERGIC3	psi-mi:“MI:0915”(physical association)	0.560
EBP	FETUB	psi-mi:“MI:0915”(physical association)	0.560
DARS2	FETUB	psi-mi:“MI:0915”(physical association)	0.560
FETUB	CREB3L1	psi-mi:“MI:0915”(physical association)	0.000
FETUB	MTIF3	psi-mi:“MI:0915”(physical association)	0.000
FETUB	ERGIC3	psi-mi:“MI:0915”(physical association)	0.000
FETUB	EBP	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (10): FETUB (Two-hybrid), FETUB (Synthetic Lethality), DARS2 (Two-hybrid), MTIF3 (Two-hybrid), ERGIC3 (Two-hybrid), EBP (Two-hybrid), CREB3L1 (Two-hybrid), HSD17B13 (Two-hybrid), RAB14 (Cross-Linking-MS (XL-MS)), FETUB (Reconstituted Complex)

ESM2 similar proteins: A0A1S3PBB7, B6S2X0, O08677, O70159, P01042, P01044, P01045, P01048, P02765, P08932, P08934, P12763, P24090, P25230, P29695, P29699, P29700, P29701, P33046, P49928, P49929, P49931, P51437, P54229, P80191, P97515, Q1KLX0, Q1KLX3, Q1KLX5, Q1KLX6, Q1KLX7, Q1KLX9, Q1KLY0, Q1KLY2, Q1KLY4, Q1KLY6, Q1KLY7, Q1KLY8, Q58D62, Q5KQS1

Diamond homologs: A0A0K0IP23, G5ECM9, G5EDZ9, O08677, P01048, P08932, P08934, P22085, P31726, P90698, Q6QZV5, Q9LEI7, Q9UGM5, P04196, P33433, Q28640, Q58D62, Q99PS8, Q9ESB3, A0A1S3PBB7, O76096, O89098, P01042, P01044, P01045, Q15828, O70159, P02765, P12763, P24090, P29695, P29699, P29700, P29701, P80191, P97515, Q5KQS1, Q5KQS2, Q5KQS3, Q5KQS4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

74 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	54
Likely benign	7
Benign	7

Top pathogenic / likely-pathogenic (0)

SpliceAI

1538 predictions. Top by Δscore:

Variant	Effect	Δscore
3:186651217:GCCT:G	acceptor_gain	1.0000
3:186636229:G:GG	donor_gain	0.9900
3:186640674:GAA:G	donor_gain	0.9900
3:186640690:G:GG	donor_gain	0.9900
3:186641141:G:GG	donor_gain	0.9900
3:186644749:A:AG	acceptor_gain	0.9900
3:186644750:G:GG	acceptor_gain	0.9900
3:186646246:AGTG:A	acceptor_gain	0.9900
3:186646247:GTGG:G	acceptor_gain	0.9900
3:186650627:A:AG	acceptor_gain	0.9900
3:186650628:G:GG	acceptor_gain	0.9900
3:186651213:TTTA:T	acceptor_loss	0.9900
3:186651215:TA:T	acceptor_loss	0.9900
3:186651216:A:AC	acceptor_loss	0.9900
3:186651216:A:AG	acceptor_gain	0.9900
3:186651216:AGCCT:A	acceptor_gain	0.9900
3:186651217:G:GG	acceptor_gain	0.9900
3:186651217:GC:G	acceptor_gain	0.9900
3:186651217:GCCTG:G	acceptor_gain	0.9900
3:186651297:CACAG:C	donor_loss	0.9900
3:186651298:ACAGG:A	donor_loss	0.9900
3:186651299:CAG:C	donor_loss	0.9900
3:186651300:AGG:A	donor_loss	0.9900
3:186651301:GGT:G	donor_loss	0.9900
3:186651303:T:G	donor_loss	0.9900
3:186640458:A:AG	acceptor_gain	0.9800
3:186640458:AGAAT:A	acceptor_gain	0.9800
3:186640459:G:GG	acceptor_gain	0.9800
3:186640459:GAATG:G	acceptor_gain	0.9800
3:186640675:A:T	donor_gain	0.9800

AlphaMissense

2469 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:186642483:T:A	C117S	0.980
3:186642484:G:C	C117S	0.980
3:186640657:G:C	R66P	0.967
3:186642543:T:A	C137S	0.966
3:186642544:G:C	C137S	0.966
3:186651230:T:A	C237S	0.964
3:186651231:G:C	C237S	0.964
3:186652554:T:C	F358L	0.955
3:186652556:C:A	F358L	0.955
3:186652556:C:G	F358L	0.955
3:186640566:T:A	C36S	0.953
3:186640567:G:C	C36S	0.953
3:186640619:C:A	N53K	0.951
3:186640619:C:G	N53K	0.951
3:186652584:T:A	C368S	0.948
3:186652585:G:C	C368S	0.948
3:186642483:T:C	C117R	0.946
3:186651281:T:A	C254S	0.944
3:186651282:G:C	C254S	0.944
3:186642544:G:A	C137Y	0.943
3:186646278:T:G	Y209D	0.943
3:186642545:T:G	C137W	0.942
3:186642543:T:C	C137R	0.941
3:186646279:A:C	Y209S	0.941
3:186644846:T:C	S174P	0.940
3:186642484:G:A	C117Y	0.936
3:186642485:C:G	C117W	0.934
3:186641055:T:C	L84P	0.930
3:186642489:G:C	A119P	0.927
3:186646278:T:C	Y209H	0.927

dbSNP variants (sampled 300 via entrez): RS1000123933 (3:186639445 T>A), RS1000456445 (3:186638650 T>C), RS1000745700 (3:186647708 A>G), RS1000755221 (3:186641944 G>A,C), RS1000878979 (3:186653590 C>T), RS1000927591 (3:186644270 C>T), RS1001232522 (3:186651745 A>C), RS1001546915 (3:186641751 A>G), RS1001730324 (3:186641766 G>A), RS1001801090 (3:186636039 C>T), RS1001997829 (3:186653228 A>C), RS1002101356 (3:186635784 T>C), RS1002666818 (3:186650625 G>A), RS1002769630 (3:186646145 T>C), RS1003092670 (3:186650905 C>A)

Disease associations

OMIM: gene MIM:605954 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST001574_5	Activated partial thromboplastin time	1.000000e-111
GCST008478_16	Neurological blood protein biomarker levels	2.000000e-11
GCST010796_2394	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_2395	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2396	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08
GCST010796_2397	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-08
GCST010796_2398	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004327	electrocardiography

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	decreases expression	3
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	3
Aflatoxin B1	decreases methylation, affects expression, decreases expression	3
Cyclosporine	decreases expression, affects cotreatment, affects expression	2
methyleugenol	decreases expression	1
bisphenol A	decreases methylation	1
sodium arsenate	decreases expression, increases abundance	1
sodium arsenite	decreases expression	1
nickel sulfate	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
obeticholic acid	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
Allergens	increases expression	1
Arsenic	decreases expression, increases abundance	1
Arsenicals	decreases expression	1
Chenodeoxycholic Acid	affects cotreatment, increases expression	1
Chlorpromazine	affects cotreatment, affects expression	1
Cholic Acids	affects cotreatment, affects expression	1
Deoxycholic Acid	affects cotreatment, increases expression	1
Estradiol	decreases expression	1
Formaldehyde	decreases expression	1
Glycochenodeoxycholic Acid	affects cotreatment, increases expression	1
Glycocholic Acid	affects cotreatment, increases expression	1
Glycodeoxycholic Acid	increases expression, affects cotreatment	1
Methyltestosterone	affects expression, affects cotreatment	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	affects expression	1
Triclosan	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.